Ontology highlight
ABSTRACT:
SUBMITTER: Shagisultanova E
PROVIDER: S-EPMC8742793 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
Shagisultanova Elena E Crump Lyndsey S LS Borakove Michelle M Hall Jessica K JK Rasti Aryana R AR Harrison Benjamin A BA Kabos Peter P Lyons Traci R TR Borges Virginia F VF
Molecular cancer therapeutics 20211102 1
Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 complex, which drives cell-cycle progression and development of therapeutic resistance. Therefore, we hypothesized that co-targeting of ER, HER2, and CDK4/6 may result in improved tumoricidal activity and suppress drug-resistant subclones that arise o ...[more]